Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2021

View Archived Issues

Enrollment begins in phase I/II study of etrumadenant in metastatic colorectal cancer

Brain-penetrant ALK inhibitor NUV-655 active against treatment-resistant mutations

Phase I trials planned for new PARP1/2 inhibitor RP-12146

AP-101 appears to be safe and well tolerated in phase I study in ALS patients

Aurigene CD73 inhibitor AU-21218 inhibits tumor growth in vivo

First patients dosed in SAVE 1 phase IIa study ATI-2173

FDA clears IND application for APB-102 as treatment of SOD1 ALS

FDA grants IND approval for Zofin in the treatment of osteoarthritis

Dosing starts in phase I study of AL-102 in combination with WVT-078 in patients with MM

AUT-00206 improves auditory information processing in patients with schizophrenia

Novartis and Gilead Sciences patent compounds for herpes virus infections

Nirogyone Therapeutics discloses MCT inhibitors

Boragen identifies new JAK inhibitors

Innovo Therapeutics synthesizes new immunomodulators

Sangamo Therapeutics presents new compounds for prion diseases

UCB-0599 shows safety in older individuals with PD with age-related comorbidities

Targeting the adenosine pathway for cancer immunotherapy

SAB-185 studied as part of ACTIV-2 trial for treatment of COVID-19

AN-3025: an anti-TNFR2 antibody for cancer immunotherapy

Valneva begins pivotal trial of COVID-19 vaccine candidate VLA-2001

Treatment begins in clinical trial of GNT-0004 gene therapy for Duchenne muscular dystrophy

Bharat reports second interim analysis of phase III study of Covaxin COVID-19 vaccine candidate

PCSK9 affects antitumor immunity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...